A Mab A Case Study In Bioprocess Development __full__ < QUICK >

The A-Mab Case Study is a seminal 2009 document developed by the CMC-Biotech Working Group—a consortium including Amgen, Genentech, and Pfizer—to demonstrate how Quality by Design (QbD) principles can be applied to monoclonal antibody (mAb) bioprocessing. It serves as a practical roadmap for implementing International Council for Harmonisation (ICH) guidelines Q8(R2), Q9, and Q10 in a biotechnology environment. Core Framework of the A-Mab Study

Design Space: The study utilizes a Design of Experiments (DoE) approach at a 2L scale to define a "scale-independent" design space. This ensures that parameters like dissolved oxygen (set at ~60%) and nutrient feeding strategies remain effective at commercial scales. 3. Downstream Process Development a-mab-case-study-version.pdf - ISPE A Mab A Case Study In Bioprocess Development

Success in mAb development isn't just about high titers; it's about building a scalable, data-driven process that ensures purity from the very first flask. downstream purification details for your project? The A-Mab Case Study is a seminal 2009

The first step in the bioprocess development of A Mab was the creation of a stable and productive cell line. A Mab was produced in a Chinese Hamster Ovary (CHO) cell line, which is a commonly used host for the production of therapeutic proteins. The CHO cell line was transfected with a plasmid containing the gene encoding A Mab, and a clone with high productivity and stability was selected. This ensures that parameters like dissolved oxygen (set